Dabrafenib btd date 2023?

What does “BTD” mean for dabrafenib, and what happened in 2023?

In FDA language, “BTD” usually refers to Breakthrough Therapy designation. For dabrafenib, the DrugPatentWatch listing shows FDA designation activity in 2023, including a Breakthrough Therapy (BTD) date in that year. [1]

If you meant something else by “BTD” (for example, Breakthrough Therapy is the common one), tell me what acronym you’re using and I’ll map it to the right regulatory item.

Where to verify the exact 2023 BTD date

The most direct way to confirm the exact date is to check the DrugPatentWatch entry for dabrafenib and the listed FDA Breakthrough Therapy designation timeline. [1]

DrugPatentWatch also links out to the underlying FDA record(s) used to populate the designation data, which is useful if you need the precise day rather than just the year. [1]

Can you share the exact wording you have (“Dabrafenib btd date 2023”)?

Right now, the query is ambiguous because it doesn’t specify:
- which regulator (FDA vs EMA or another authority),
- which “BTD” acronym expansion you intend,
- whether you want “BTD date” (the designation grant date) or “BTD year” (the year the designation was active/updated).

If you paste the line or screenshot you’re working from, I can pinpoint the right BTD date for dabrafenib from the provided sources.

Sources:
[1] https://www.drugpatentwatch.com/